ALLMedicine™ Hereditary Hemorrhagic Telangiectasia Center

Feb 4th, 2021 - A 54-year-old man with hereditary hemorrhagic telangiectasia and severe hypoxemia was referred for lung transplantation. Embolization had not been performed because of numerous bilateral small pulmonary arteriovenous malformations. Although he app...

Jan 25th, 2021 - Cerebrovascular malformations occur in both sporadic and inherited patterns. This paper reviews imaging and clinical features of cerebrovascular malformations with a genetic basis. Genetic diseases such as familial cerebral cavernous malformations...

Jan 7th, 2021 - Retrospective questionnaire and healthcare administrative data suggest reduced life expectancy in untreated hereditary hemorrhagic telangiectasia (HHT). Prospective data suggests similar mortality, to the general population, in Denmark's centre-tr...

Dec 30th, 2020 - Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence.|2020|Kilian A,Clancy MS,Olitsky S,Gossage JR,Faug...

Dec 23rd, 2020 - Cerebral and spinal cord high-flow arteriovenous fistulae (HFAVF) are part of the spectrum of lesions found in Hereditary Hemorrhagic Telangiectasia (HHT). HFAVF consist of communications between large arteries and veins without interposed nidi or...

Sep 7th, 2020 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and c...

Apr 6th, 2020 - Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.|2020|Silv...

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and c...

Feb 4th, 2021 - A 54-year-old man with hereditary hemorrhagic telangiectasia and severe hypoxemia was referred for lung transplantation. Embolization had not been performed because of numerous bilateral small pulmonary arteriovenous malformations. Although he app...

Jan 25th, 2021 - Cerebrovascular malformations occur in both sporadic and inherited patterns. This paper reviews imaging and clinical features of cerebrovascular malformations with a genetic basis. Genetic diseases such as familial cerebral cavernous malformations...

Jan 7th, 2021 - Retrospective questionnaire and healthcare administrative data suggest reduced life expectancy in untreated hereditary hemorrhagic telangiectasia (HHT). Prospective data suggests similar mortality, to the general population, in Denmark's centre-tr...

Jan 7th, 2021 - HHT care at Mayo Clinic Mayo Clinic is a hereditary hemorrhagic telangiectasia (HHT) Center of Excellence. This means that Mayo Clinic has been designated by Cure HHT as being experts in diagnosing and treating all aspects of this disorder. Mayo C...

Jan 7th, 2021 - Overview Hereditary hemorrhagic telangiectasia (tuh-lan-jee-uk-TAY-zhuh) is an inherited disorder that causes abnormal connections, called arteriovenous malformations (AVMs), to develop between arteries and veins. The most common locations affecte...

Sep 29th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 29th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 9th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Sep 9th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Jun 17th, 2020 - Bevacizumab has shown efficacy in the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare, progressive bleeding disorder for which there are currently no approved therapies. The finding comes from the InHIBIT-Bleed trial, results from...